Free Trial

Tempest Therapeutics (TPST) Stock Price, News & Analysis

$2.23
+0.06 (+2.76%)
(As of 07/12/2024 ET)
Today's Range
$2.16
$2.24
50-Day Range
$2.01
$3.73
52-Week Range
$0.17
$9.77
Volume
525,263 shs
Average Volume
2.29 million shs
Market Capitalization
$49.55 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.75

Tempest Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
830.5% Upside
$20.75 Price Target
Short Interest
Bearish
10.77% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.60mentions of Tempest Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
Acquiring Shares
$100,001 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.57) to ($1.64) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.15 out of 5 stars

Medical Sector

566th out of 912 stocks

Pharmaceutical Preparations Industry

269th out of 434 stocks

TPST stock logo

About Tempest Therapeutics Stock (NASDAQ:TPST)

Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.

TPST Stock Price History

TPST Stock News Headlines

Catalyst Could Trigger 10,000% Crypto Gains
Are you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealthy beyond your wildest dreams. Just take a look:
Catalyst Could Trigger 10,000% Crypto Gains
Are you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealthy beyond your wildest dreams. Just take a look:
TPST Stock Earnings: Tempest Therapeutics Beats EPS for Q1 2024
See More Headlines
Receive TPST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tempest Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/09/2024
Today
7/14/2024
Next Earnings (Estimated)
8/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:TPST
Fax
N/A
Employees
17
Year Founded
2012

Price Target and Rating

Average Stock Price Target
$20.75
High Stock Price Target
$47.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+830.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-29,490,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.39 per share

Miscellaneous

Free Float
21,491,000
Market Cap
$49.55 million
Optionable
Optionable
Beta
-1.73

Social Links

The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Stephen R. Brady J.D. (Age 54)
    LLM, CEO, President & Director
    Comp: $923.24k
  • Mr. Nicholas Maestas (Age 43)
    VP of Strategy & Finance and Secretary
    Comp: $465.43k
  • Dr. Samuel Whiting M.D. (Age 58)
    Ph.D., Executive VP & Chief Medical Officer
    Comp: $667.65k
  • Mr. Justin Trojanowski (Age 36)
    Corporate Controller, Treasurer & Principal Accounting Officer
  • Ms. Lindsay Young
    Head of Human Resources
  • Dr. Sharon Sakai Ph.D.
    RAC, Head of Regulatory & Quality

TPST Stock Analysis - Frequently Asked Questions

How have TPST shares performed this year?

Tempest Therapeutics' stock was trading at $4.40 at the start of the year. Since then, TPST stock has decreased by 49.3% and is now trading at $2.23.
View the best growth stocks for 2024 here
.

How were Tempest Therapeutics' earnings last quarter?

Tempest Therapeutics, Inc. (NASDAQ:TPST) posted its quarterly earnings data on Thursday, May, 9th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.08.

When did Tempest Therapeutics' stock split?

Tempest Therapeutics's stock reverse split before market open on Friday, June 25th 2021. The 1-15 reverse split was announced on Friday, June 25th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 28th 2021. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

How do I buy shares of Tempest Therapeutics?

Shares of TPST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TPST) was last updated on 7/14/2024 by MarketBeat.com Staff

From Our Partners